Liron Bar-Peled, Ph.D.

Research

There is a large unmet need for therapeutic options for patients with epithelial ovarian cancer, most succumb to the disease within five years. The Bar-Peled lab aims to open a new area of therapeutic discovery by demonstrating that certain proteins known to drive cancer are "druggable" when they were previously thought not to be. My new mapping technique has provided several proteins that are appealing targets for future therapies but are conventionally considered "undruggable." I will now use cancer cells and patient samples to target these undruggable proteins to prevent cancer growth. Using findings from these initial studies, I will identify additional druggable proteins that, when inhibited, may help combat ovarian cancer. With these novel approaches, my work has the potential to rapidly accelerate progress in the search for new cancer treatments.